ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. ASC30 oral tablet was generally safe and well tolerated. All adverse events (AEs) were mild (grade 1) or moderate (grade 2), and most of the AEs were gastrointestinal (GI)-related. There were no grade 3 or higher AEs as well as no serious AEs (SAEs). Alanine aminotran ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

In an unexpected move, Viking Therapeutics, Inc (NASDAQ: VKTX ) has been sold off hard since Donald Trump won the U.S. elections. A lot of the excitement in GLP-1s has disappeared in the last few months, despite noMark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real- ...

Novo Nordisk A/S TodayNVONovo Nordisk A/S$108.47 +0.46 (+0.43%) 52-Week Range$99.42▼$148.15Dividend Yield0.66%P/E Ratio35.10Price Target$150.40Add to WatchlistRecent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed through the names Ozempic and Wegovy, sales of the drugs grew 32% and 76% through the first nine months of 2024, compar ...

BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head with Tirzepatide from Eli Lilly and Company (NYSE: LLY) in the US (NCT06737042). GZR18 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being developed ...

CHICAGO, Dec. 12, 2024 /PRNewswire/ -- With the rising popularity of GLP-1 medications among Americans for diabetes and weight management, Conagra Brands is proud to announce a first-of-its-kind initiative in the food industry. Starting in January 2025, the company's Healthy Choice® line will feature an "On Track" badge on 26 select items, indicating that the products are high in protein, low calorie, and a good source of fiber, which make these items "GLP-1 friendly." Healthy Choice is the first major food ...

There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized healthcare company. It may even lead to an acquisition.In the past month, however, excitement around Viking has cooled, considerably. During November, the stock fell by 27%, hitt ...

After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. The safety and tolerability of GZR18 tablets align with the known safety characteristics of GLP-1 receptor agonists, with no unexpected safety signals during the study.BEIJING, Nov. 12, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stoc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State o ...

Global Partners LP Common Units (NYSE:GLP) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Sean Geary - CLO & Secretary Conference Call Participants Selman Akyol - Stifel Operator Good day, everyone, and welcome to the Global Partners Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded. [Operator Instructions]. With us from Global Partners are President and Chief Executiv ...